Guidelines and policies
Find useful guidelines and policies for professionals working with lipid conditions
ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019): The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Source: European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Low density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Panel
Source: European Heart Journal
Joint British Societies for the Prevention of Cardiovascular Disease (2014) Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3)
National Institute for Health and Care Excellence (2014) Cardiovascular disease: risk assessment and reduction, including lipid modification
Scottish Intercollegiate Guidelines Network (SIGN) Risk estimation and the prevention of cardiovascular disease.
Public Health England (2014) Adult obesity and type 2 diabetes.
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement (2022).
Source: European Atherosclerosis Society